Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations

v3.22.1
Condensed Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 2,769,102 $ 1,706,957
General and administrative expenses 1,192,112 1,350,476
Total operating expenses 3,961,214 3,057,433
Loss from operations (3,961,214) (3,057,433)
Other income:    
Interest income 906 1,400
Total other income 906 1,400
Loss before income taxes (3,960,308) (3,056,033)
Net loss $ (3,960,308) $ (3,056,033)
Basic net loss per share $ (0.48) $ (0.37)
Diluted net loss per share $ (0.48) $ (0.37)
Weighted average number of shares outstanding - basic 8,330,390 8,326,010
Weighted average number of shares outstanding - diluted 8,330,390 8,326,010